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Escape from Tumor Dormancy Following Gene- Or Viro- therapies is Mediated 
by Acquisition of a Phenotype in which Innate Immune Surveillance Actively 
Drives Tumor Cell Recurrence. 
Tim Kottke, Diana Rommelfanger, Kevin Shim, Jose Pulido, Jill Thompson, Karishma 
Rajani, Oleg Bobr, Peter Selby, Elizabeth Ilett, Alan Melcher, Richard Vile.  
 
When established (~0.3-0.5cm) primary murine B16 tumors are treated with either 
cytotoxic gene therapy (HSVtk/GCV), oncolytic virotherapy (intra-tumoral reovirus) 
or adoptive T cell therapy, a proportion of mice will become apparently tumor free.   
However, if the animals are observed for prolonged periods of time (>60-100 days), 
the majority of mice will develop aggressively growing recurrent tumors.  Excision 
of the site of tumor injection during the period of tumor dormancy (no palpable 
tumor) indicated that residual tumor cells are readily detectable in most mice by 
histology.  Unexpectedly, it was extremely difficult to re-grow the tumor cells from 
these specks of minimal residual disease in vitro.  However, by screening multiple 
cytokines for their ability to support re-growth of recurrent B16 cells, we identified 
TNF-D as a major growth factor for recurrent cells.  Conversely, treatment of 
primary B16 populations with TNF-D led to highly significant reductions in tumor 
cell viability.  Similarly, depletion of NK cells, or antibody blockade of TNF-D, from 
C57Bl/6 mice led to significantly increased tumorigencity of primary B16 tumors.  
In contrast, depletion of NK cells allowed for decreased tumorigenicity of TNF-D 
stimulated recurrent B16 cells recovered from mice in a state of minimal residual 
disease.  These data suggest that tumor recurrence may be mediated by a distinct 
phenotypic switch in vivo.  Thus, initially, primary tumor cells are highly sensitive to 
innate immune cell surveillance through NK cells and TNF-D.  However, escape from 
dormancy in vivo is associated with acquisition of a phenotype in which such TNF-
D-mediated immune surveillance actively drives tumor growth.  TNF-D growth 
promoted recurrent cells also expressed high levels of PD-L1 compared to primary 
tumor cells, suggesting that this may be a further mechanism by which recurrences 
could emerge in vivo, even in the presence of anti tumor T cell responses.  Consistent 
with this hypothesis, recurrence was significantly inhibited in vivo following gene, 
viro- or adoptive T cell therapies, by treatment with TNF-D blockade or systemic 
checkpoint inhibitor therapy.   
 
